Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, which are implicated in the dysregulation of complex diseases. By integrating AI with advanced experimental technologies, the company aims to create therapies for conditions previously considered undruggable.
Funding
$286.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Founders
Product
Problem
Many complex diseases lack effective treatments because the underlying biological mechanisms are not well understood or the therapeutic targets are considered undruggable. Traditional drug discovery approaches often fail to address the root causes of these diseases, leaving significant unmet medical needs.
Solution
Dewpoint Therapeutics is pioneering a novel drug discovery platform that targets biomolecular condensates, dynamic structures within cells that play a critical role in regulating cellular function. The dysregulation of these condensates is implicated in a wide range of diseases, including cancer, neurodegenerative disorders, and metabolic diseases. Dewpoint's platform integrates advanced experimental technologies with artificial intelligence and machine learning to identify and develop condensate-modulating drugs (c-mods). These c-mods offer a new approach to modulating the function of previously undruggable targets, opening up new possibilities for treating complex diseases. The company's integrated platform enables the discovery of novel therapeutic targets and the design of small molecule drugs that can selectively modulate condensate function, restoring normal cellular processes and addressing the underlying causes of disease.
Target Audience
Dewpoint Therapeutics primarily targets pharmaceutical companies seeking innovative drug discovery platforms and novel therapeutic candidates for complex and previously undruggable diseases.
Features
- AI/ML-powered platform for identifying and validating biomolecular condensates as therapeutic targets
- Proprietary chemical library of condensate-modulating small molecules (c-mods)
- High-throughput screening assays for identifying c-mods that selectively modulate condensate function
- Integrated suite of state-of-the-art experimental technologies for characterizing condensate structure and function
- Development of orally bioavailable c-mods with demonstrated activity in preclinical models
- Therapeutic pipeline spanning multiple disease areas, including oncology, neurodegeneration, cardiopulmonary, and metabolic diseases